WO1992017206A1 - Wound healing - Google Patents
Wound healing Download PDFInfo
- Publication number
- WO1992017206A1 WO1992017206A1 PCT/GB1992/000570 GB9200570W WO9217206A1 WO 1992017206 A1 WO1992017206 A1 WO 1992017206A1 GB 9200570 W GB9200570 W GB 9200570W WO 9217206 A1 WO9217206 A1 WO 9217206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- composition according
- neutralising agent
- tgf
- agent
- Prior art date
Links
- 230000029663 wound healing Effects 0.000 title description 19
- 239000003102 growth factor Substances 0.000 claims abstract description 113
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 72
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 71
- 206010052428 Wound Diseases 0.000 claims abstract description 69
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 32
- 231100000241 scar Toxicity 0.000 claims abstract description 28
- 230000035876 healing Effects 0.000 claims abstract description 27
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 21
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 15
- 230000009772 tissue formation Effects 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 15
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 102000005962 receptors Human genes 0.000 claims description 14
- 108020003175 receptors Proteins 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 230000002262 irrigation Effects 0.000 claims description 4
- 238000003973 irrigation Methods 0.000 claims description 4
- 238000002604 ultrasonography Methods 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 102000004237 Decorin Human genes 0.000 claims description 3
- 108090000738 Decorin Proteins 0.000 claims description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 claims description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 claims description 3
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 3
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229920000642 polymer Polymers 0.000 claims description 3
- 239000003087 receptor blocking agent Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 102000004954 Biglycan Human genes 0.000 claims description 2
- 108090001138 Biglycan Proteins 0.000 claims description 2
- 239000007943 implant Substances 0.000 claims description 2
- 230000007935 neutral effect Effects 0.000 claims description 2
- 239000008174 sterile solution Substances 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 25
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 25
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 24
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 24
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 102000008186 Collagen Human genes 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 15
- 229920001436 collagen Polymers 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 8
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 210000002744 extracellular matrix Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 230000037390 scarring Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 229920002683 Glycosaminoglycan Polymers 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
- 208000012260 Accidental injury Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108700012441 IGF2 Proteins 0.000 description 1
- 206010021519 Impaired healing Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003112 degranulating effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 230000019305 fibroblast migration Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- -1 for example Polymers 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 239000012859 tissue stain Substances 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- This invention relates to the healing of wounds and to agents and techniques for facilitating repair and healing of animal tissue, especially, but not exclusively, skin or other epithelial tissue, that has been damaged by, for example, wounds resulting from accidental injury, surgical operations or other trauma.
- the invention has particular reference to the healing of wounds in humans and other vertebrates.
- ⁇ CX extra ⁇ cellular matrix
- wound healing in tissues such as skin is generally a reparative process, in contrast to a regenerative process which appears to take place in healing of fetal and embryonic tissue.
- the outcome of a wound repair process appears to be influenced by a number of different factors, including both intrinsic parameters, e.g. tissue oxygenation, and extrinsic parameters, e.g. wound dressings.
- intrinsic parameters e.g. tissue oxygenation
- extrinsic parameters e.g. wound dressings.
- Such growth factors that have been identified and isolated are generally specialised soluble proteins or polypeptides and include transforming growth factor alpha (TGF-c ), transforming growth factor beta (TGF- ⁇ l, TGF-B2, TGF-B3 etc), platelet derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth factors I and II (IGFI and IGFII) and acidic and basic fibroblast growth factors (acidic FGF and basic FGF) . Many of these growth factors have already been made by genetic engineering using recombinant DNA technology.
- compositions for use in the treatment of wounds to inhibit scar tissue formation during healing comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
- the TGF- ⁇ growth factor family is believed to have a particularly important regulating role in wound repair, especially in adult animals, as a stimulant of macrophage infiltration, fibroblast migration, and extracellular matrix synthesis, especially collagen synthesis and deposition by fibroblasts which are involved in the production cf scar tissue.
- Other growth factors e.g. PBGF
- PBGF fibroblast migration, and extracellular matrix synthesis, especially collagen synthesis and deposition by fibroblasts which are involved in the production cf scar tissue.
- Other growth factors e.g. PBGF
- PBGF aisc ⁇ .ant in this process and, to some extent, are believed to act in cooperation with one another in the complex overall regulatory process that is involved in wound healing.
- PCT/US90/05566 discloses the general use of antibodies to TGF- ⁇ to reduce fibrosis in a rat kidney nephrosis induced model.
- TGF- ⁇ growth factors are fibrotic and that supressing the activity of
- TGF ⁇ -1 and TGFfi-2 mentions TGF ⁇ -1 and TGFfi-2 as having the function of increasing extracellular matrix production, but does not suggest that any particular TGF ⁇ does not have such an effect.
- the growth factor neutralising agent may be a growth factor neutralising antibody, for example antibodies to TGF- ⁇ l, TGF-B2 and PDGF.
- the growth factor neutralising agent may be a growth factor receptor blocking agent, for example a peptide containing the receptor binding site of the growth factors TGF- ⁇ l, TGF-B2 or PDGF, for example.
- the growth factor neutralising agent may also comprise a molecule which binds to the growth factor to inhibit receptor binding, for example where the growth factor is selected from TGF- ⁇ l and TGF-B2, the molecule may be selected from Decorin and Biglycan.
- the growth factor neutralising agent may also be an antisense oligonucleotide or ribosyme(s) to growth factor mRNA, which both act to prevent mRNA from being translated.
- the growth factor neutralising agent may also be a soluble form of the receptor or the growth factor binding domain of the receptor.
- the growth factor neutralising agent may be present in the composition in an active form.
- the growth factor neutralising agent may be present in an inactive form.
- One method of inactivating the growth factor neutralising agent is encapsulation, whereby the capsules may be degradable by an external stimulus to release the active, growth factor neutralising agent when required.
- the external stimulus may include UV light, in vivo enzymes, ultrasound or heat.
- a second method of inactivating the growth factor neutralising agent may be by the molecular addition of a bindin ⁇ molecule. Again, the binding molecule may be detached from the complex to release active growth factor neutralising agent by an external stimulus including UV light, in vivo enzymes, ultrasound or heat.
- the pharmaceutically acceptable carrier may comprise a neutral sterile cream, gel or powder for topical application, or a sterile solution for injection, irrigation or inhalation or an aerosol, or may comprise a sterile dressing for topically covering a wound or may be in the form of a tablet or capsule for enteral administration, or the carrier may comprise a biopolymer patch or a slow release device for implantation.
- composition may also comprise active cytokines, for example fibroblast growth factor or factors or other cell proliferation or migration stimulating or glyco- aminoglycan stimulating factors in a ratio sufficient to accelerate wound healing in addition to the growth factor neutralising agent(s) reducing wound scarring.
- active cytokines for example fibroblast growth factor or factors or other cell proliferation or migration stimulating or glyco- aminoglycan stimulating factors in a ratio sufficient to accelerate wound healing in addition to the growth factor neutralising agent(s) reducing wound scarring.
- the invention also provides a method of preparation of a pharmaceutical composition containing the growth factor neutralising agent or agents for applying the composition topically in a cream, gel, powder or dressing; in a solution for injection, irrigation or inhalation or aerosol, or in the form cf a tablet or caosule for enteral administration.
- the pharmaceutical preparation may also comprise a biodegradable polymer forming a patch, or an implantable control release device, useful in surgical operations having a large initial release followed by a slower release later. It will be appreciated that this list is not exhaustive, many other types of compositions being possible, such as might readily occur to one skilled in the art.
- the method of preparation of the composition may also include a composition comprising active cytokines.
- the invention also provides a method of inhibiting scar tissue formation during the healing of wounds, said method consisting in adminstering to a host suffering from tissue wounding a growth factor neutralising agent or agents in the wound area in a dosage effective to reduce activity of one or more growth factors involved in the process that leads to the formation of scar tissue during healing.
- the inhibitory agent or mixture of agents employed for this purpose comprises a neutralising antibody or antibodies specific to one or more of the growth factors concerned, or to precursors cf such growth factors.
- such antibody cr eacr. such antibody is a monoclonal antibody obtained __y recombinant DNA techniques.
- polyclonal antibodies purified for example by affinity chromo- tography from antiserum prepared by injection of relevant growth factor(s) in an appropriate host, may also be used quite satisfactorily as an alternative, as has been the case in most of the preliminary experimental investigations.
- fragments thereof (Fab's) retaining the specific antigen binding characteristics can also be used and such fragments are intended to be included within the scope of the term "antibody” as used herein in this specification.
- the growth factors are initially present in an inactive state as part of, or as a ligand bound tc, a larger protein molecule, and are separated from the latter, e.g. by enzymic action, when released in their active form. Binding of a neutralising agent such as an antibody to such inactive protein precursors may therefore prevent or inhibit proteolytic action and release of the active growth factors which will lead to an overall neutralising effect and inhibition of activity in the same way as the alternative process of a direct binding of an inhibitory agent to the active growth factor molecules themselves or to cellular recettor sites cf such ⁇ rowth factors.
- a neutralising agent such as an antibody
- the inhibitory agent or mixture of agents may alternatively consist of a synthetic peptide or peptides that can act to antagonise or block growth factor activity, e.g. by blocking binding of the growth factor(s) at cellular receptor sites without eliciting any intracellular "second messenger" response.
- peptide "blocking" agents could have the advantage of being free of potential adverse immunogenic effects, and may passs through membrane barriers more easily than antibodies so that they would be most suitable for making up pharmaceutical formulations or compositions for topical application.
- blocking peptides may readily be designed from knowledge of the amino acid sequence of the growth factors concerned and of that portion of this sequence which is involved in binding to the cellular receptors since these peptides will need to "mimic" this binding portion of the sequence. It is, for instance, known that with TGF- ⁇ l it is the c-terminal region of the molecule that is involved in receptor binding. Similarly, the region(s) involved in receptor binding with TGF-o is the region between cys 33 and cys 42, and with EGF it is the regions between cy ⁇ 20 and cys 31, between tyrosine 14 and cys 31 and between leucine 15 and arginine 53 that are involved. With FGF's the critical receptor binding region is that between amino acids 105 and 115. _ 1
- the inhibitory growth factor neutralising agent(s) may consist of other molecular entities that act by binding directly to a growth factor or factors, or precursor(s) thereof, to inactivate the latter.
- a neutralising or inhibitory agent of this kind is Decorin which is a small chrondroitin-dermatan sulphate proteoglycan known to strongly bind TGF- ⁇ , as reported by Yamaguchi et al, Nature (1990), 346, 281-284.
- the inhibitory growth factor neutralising agent(s) may be active at the molecular level and consist of molecules active against a growth factor's mRNA.
- Such molecules may include antisense oligonucleotide(s) synthesised against one or more growth factor mRNA sequences to prevent translation thereof, or the molecule may be a ribosyme(s) targetted against specific se ⁇ uences of one or more growth factor mRNA sequences to destroy the mRNA and again prevent its translation.
- an antibody or other agent having a neutralising effect in respect of only one growth factor that is involved in the formation of scar tissue during wound healing may be quite sufficient to prevent any significant amount of scar tissue from bein ⁇ oroduced
- combined adminstration of two or more different antibodies or other inhibitory agents having a neutralising effect against two or more different growth factors concerned may be found to be even more effective, especially for relatively large excisional wounds for example.
- the different or other inhibitory agents may be administered separately but simultaneously or sequentially, or they may be made up into a mixture or "cocktail" within a single pharmaceutical formulation.
- TGF- ⁇ and/or PDGF can generally be very effective in this respect, inhibition of the activity of certain of the other growth factors may, at least on its own, be less effective under similar conditions for reducing scar tissue formation, even though such ctner growtn factors may still be necessary, or may at least have a beneficial effect, in connection with promoting wound healing.
- an inhibitory or neutralising agent or agents effective in reducing activity of a growth factor or factors e.g. TGF- ⁇ and/or PDGF having a major role in the formation of scar tissue in combination with a different exogeneous growth factor or agent which does not independently promote the formation of scar tissue to any significant extent but which, at the same time, can independently promote wound healing or provide a beneficial effect in respect of quality of healing.
- a growth factor or factors e.g. TGF- ⁇ and/or PDGF
- TGF- ⁇ and/or PDGF fibroblast growth factors
- FGF's fibroblast growth factors
- a preparation may be obtained which not only prevents scarring of a wound, but also accelerates the whole process of wound healing. It might have been anticipated that any treatment for reducing or preventing scar tissue formation would be most effectively applied at a relatively late stage of healing during the phase of tissue remodelling or reorganisation that occurs subsequent to the formation of granulation tissue which replaces fibrin initially produced in the early stages of healing. Contrary to such expectation, however, it has been found, surprisingly, that in applying the present invention the treatment with the growth factor neutralising agent or agents may need to be carried out at an early stage of healing in order to be effective.
- the treatment is best carried out before and/cr during the granulation phase whilst fibrin is still present, i.e. before the fibrin has been wholly replaced by granulation tissue.
- This will usually be within a period of about 14 days after the initial occurrence of a wound.
- treatment will be commenced earlier, within seven days or, if possible, within three days or less following wounding.
- commence treatment on the same day as wounding, or at least on the following day, and in the case of surgical wounds the commencement of this treatment, say by topical or parenteral application of the growth factor neutralising agent(s) in a pharmaceutical formulation applied to the wound area, may well be incorporated as an integral part of the surgical procedure and be applied before surgery or immediately the main surgery is completed, before or after suturing.
- the treatment does not necessarily need to be repetitive and to be continued throughout ail the phases of wound healing.
- it may often be sufficient to administer the growth factor neutralising agent(s) in an appropriate dosage once, or only a few times at most, during the early stages of wound healing. This is of course important where agents such as proteins are concerned which may tend to provoke immunological reactions, and it also gives other practical and economic advantages .
- wound strength may even be improved in that the orientation observed of the new collagen fibres or fibrils formed during healing, at least in the case of incisional dermal wounds, more closely resembled that of undamaged tissue, lying generally prallel to the outer skin surface instead of at a large angle or generally perpendicular to the outer surface as is commonly found when such wounds heal normally with formation or scar tissue.
- each group at least two animals were usually killed (by chloroform overdose on post-wounding days 7, 14, 28 and 42, and in some cases also on post-wounding days 70, 112 and 168. All four wounds were excised (with a 0.5 cm margin on ail sides immediately after death of each animal and were subjected to tissue analysis by conventional immunohistochemical, histological staining and biochemical techniques.
- each wound was bisected to provide two samples which were either frozen and/or fixed and processed for immunocytochemical staining using antibodies to coilagens I, III, IV, laminin and fibronectin or processed for routine histological examination using a variety of connective tissue stains, or they were immediately freeze-dried for biochemical analyses after microscopic dissection.
- Secondary antibodies 1, 2 and 4 were FITC conjugated (fluorescein isothiocyanate labelled) for immunofluorometric detection and measurement; 3 was biotynlated.
- the incubation with the primary antibody was for 1 hour followed by three rinses in phosphate buffered saline '? ⁇ 3 .
- Incubation with FITC-conjugated secondary antisera was for 1 hour followed bv a further three rinse with PBS.
- Immunostaining for macrophages and monocytes involved the Biotin-Streptavidine technique, i.e. after the primary incubation and rinsing, the sections were incubated with the biotynlated sheep antimouse IgG for 1 hour, rinsed with PBS three times, incubated with the fluorescein streptavidine for 20 minutes and finally washed with PBS three times.
- the sections were mounted in a non-fading medium, DABCO (l,4-diazobicyclo-(2,2,2)-octane) , and photographed using a Leitz Dialux microscope and kodak Ektachrome 400 ASA film.
- DABCO l,4-diazobicyclo-(2,2,2)-octane
- control sections were stained, substituting PBS for the primary antibody.
- the wounds were microscopically dissected out along with a piece of unwounded dorsal skin from each wound and immediately freeze-dried to constant weight.
- the tissue was homogenised in 1 ml of 1M guanidine hydrochloride, 0.15 M sodium acetate, 0.01 M EDTA, pH 5.8, for 24 hours at 4°C to extract the glycosaminoglycans.
- the homogenate was then centrifuged at 18,000 g for 1 hour. The pellet was washed twice with 0.5 ml of water and the washings added to the supernatant.
- the supernatant was dialysed against 100 mM phosphate buffer with 5 mM EDTA, pH 5.5, followed by digestion with papain 2.5 mg/ml.
- the glycosaminoglycans were precipitated with 2% CPC and separated using the method of Cappelletti et al, 1979.
- the pellets were digested with pepsin 100 ⁇ g/ml in C.5 M acetic acid at 4°C fo 24 hours. This was followed by centrifuging at 18,000 g for 1 hour. The pellet thus obtained was subjected to Hydroxyproline assay as described by Stegman and Stadler (1987); some of the supernatant was also used for this assay. To measure the ratio of type I/III collagen, the supernatant was subjected to SDS PAGE using the method of Sykes et al (1976) .
- the growth factors used in these experiments were commercially available reagents obtained from R & D Systems (Mineapolis, U.S.A.) or British Biotechnology (U.K.) or Serotec (U.K.) and included :- 1. Transforming growth factor beta-1 (TGF- ⁇ l) derived from porcine platelets - Dose 10 ng/injection.
- TGF- ⁇ l Transforming growth factor beta-1
- PDGF Platelet derived growth factor
- EGF Epidermal growth factor
- bFGF Basic Fibroblast growth factor
- Acidic Fibroblast growth factor (aFGF) derived from bovine brain - Dose 10 ng/injection.
- the growth factor neutralising antibodies use ⁇ in these experiments were also reagents commercially available as detailed above and were of known neutralising potency. They included :
- TGF Beta neutralising antibody (raised in rabbit against native porcine platelet TGF- ⁇ l - neutralises both TGF ⁇ -1 and TGF ⁇ -2) - Dose 50 ug/injection.
- PDGF neutralising antibody (raised in goats against native human PDGF) - Dose 20 ⁇ qf injection.
- EGF neutralising antibody polyclonal antibody raised in mouse against human EGF
- Basic FGF neutralising antibody (raised in rabbits against native bovine brain basic FGF . - Dose 30 ⁇ g/i jection.
- Acidic FGF neutralising antibody (raised in rabbit against native bovine brain acidic FGF ⁇ - Dose 30 ⁇ g/injection.
- the irrelevant antibodies used for the sham control wounds were either rabbit IgG or goat IgG according to the host in which neutralising antibody tc the growth factor was raised.
- the dose of the irrelevant antibody was similar to that of the neutralising antibody.
- wounds which showed a distinct scar with vertically orientated, parallel, and densely packed collagen fibrils. These effects were most marked in the papillary dermis and subcutaneous tissues.
- Wounds treated with neutralising antibodies to TGF- ⁇ or PDGF also showed a marked reduction in fibronectin, particularly in the reticular dermis, with an orientation pattern similar to that of the collagen fibrils. Although fibronectin staining was markedly reduced throughout the wound, it was still brightest at the dermal/epidermal junction.
- Treatment with neutralising antibodies to TGF- ⁇ and PDGF also decreased the number of blood vessels, monocytes and macrophages within the healing wound.
- the positive control wounds treated with TGF- ⁇ and PDGF showed a marked increase in extracellular matrix accumulation, in the density of extracellular matrix packing and in the number of blood vessels, monocytes and macrophages. Scarring was more prominent in these growth factor treated wounds compared to controls.
- TGF- ⁇ at least, which appears to be highly active i__ connection with the production and organisation of collagen, especially collagen I, leading to tne formation of scar tissue
- the level of this growth factor in the environment of the wound may increase quite quickly by means of an auto-catalytic cascade effect.
- the TGF- ⁇ present within an initial wound from platelet degradation act as a chemoattractant to monocytes, macrophages and fibroblasts at increasing concentrations, but it also feeds back on its own promoter to stimulate its own synthesis so that high levels can soon arise.
- the inflammatory cells, especially macrophages release TGF- ⁇ and exhibit this auto-inductive effect on TGF- ⁇ synthesis.
- TGF- ⁇ also stimulates the synthesis and release of other growth factors, e.g. TGF- ⁇ X, PDGF, EGF. TGF- ⁇ , and these other growth factors stimulate the synthesis of extracellular matrix molecules, e.g. collagens and glycosaminoglycans, by the wound fibroblasts and also influence the degree of proteolytic turnover and organisation of these extracellular matrix molecules.
- extracellular matrix molecules e.g. collagens and glycosaminoglycans
- an appropriate amount of growth factor antibody or antibodies or other growth factor inhibitory agent(s), constituting the material effective in neutralising and/or in modifying the profile of relevant growth factors active and responsible for scar tissue formation in the healing of wounds will be made up by any of the methods well-known in the art of pharmacy as a pharmaceutical formulation or prepar ⁇ ation for administration in any suitable manner to a patient in need of wound treatment.
- Such pharmaceutical formulations or preparations may, moreover, be presented not only individually for clinical use but they may also be presented as components of first aid kits for example for non-clinical emergency use.
- the antibody or antibodies or other neutralising agent(s) should be administered (at least for incisional wounds) so as to effectively neutralise between 1 pg - 1 ⁇ g TGF- ⁇ (1 and 2 ) and/cr PDGF (but preferably an amount of between 100 pg - 1C ng) per cm linear incision per administration.
- application early in the wound healing process is essential. Normally this will be before, during or before and during, the phase of * granulation tissue formation, within about 14 days, but preferably within 7 or 3 days, or less, following wounding.
- the pharmaceutical preparations may convenientl be applied topically by application to the surface around the wound in liquid, gel, aerosol, cream or powder form, or in the form of a dressing, biodegradeable patch or control release implantable device at the time of wounding or shortly thereafter.
- Parenterai adminstration, especially subcutaneous injection may also often be preferred so that the neutralising antibodv or antibodies or ether agentfs can be introduced directly into the wound environment for maximum efficiency.
- the pharmaceutical formulations prepared may comprise sterile liquid preparations (e.g. in phosphate buffered saline) of a predetermined amount of the active material, e.g. relevant antibody or antibodies, presented in unit dosage form and contained in sealed ampoules ready for use.
- the formulations may be made up with the active material in intimate association or admixture with at least one other ingredient constituting a compatible pharmaceutically acceptable carrier, diluent or excipient in order to provide a composition, such as a cream, gel, ointment or the like, which is most suitable for topical application.
- a compatible pharmaceutically acceptable carrier such as a cream, gel, ointment or the like
- the formulation may be applied to a sterile dressing, biodegradable/ absorbable patches or dressings for topical application, or to slow release implant systems with a high initial release decaying to a slow release.
- the formulation may also consist of a neutralising agent, for example, relevent antibody or antibodies, attached to a carrier, for example, a biopolymer of collagen or hyaluronic acid or a polymer, for example, PVC, from which it can be released quickly initially and more slowly in the longer term when applied to, or implanted within, the wound or tissue viod.
- a neutralising agent for example, relevent antibody or antibodies
- a carrier for example, a biopolymer of collagen or hyaluronic acid or a polymer, for example, PVC
- the invention provides a numbe. of different aspects and, in general, it embraces ail novel and inventive features and aspects herein disclosed, either explicitly or implicitly and either singly or in combination with one another. Moreover, the scope of the invention is not to be construed as being limited by the illustrative examples or by the terms and expressions used herein merely in a descriptive or explanatory sense.
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92907214A EP0585242B2 (en) | 1991-03-28 | 1992-03-30 | Wound healing |
CA002105652A CA2105652C (en) | 1991-03-28 | 1992-03-30 | Reducing wound scarring with antibodies to growth factors |
DK92907214T DK0585242T4 (en) | 1991-03-28 | 1992-03-30 | Wound healing |
US08/122,508 US5662904A (en) | 1991-03-28 | 1992-03-30 | Anti-scarring compositions comprising growth factor neutralizing antibodies |
DE69229729T DE69229729T3 (en) | 1991-03-28 | 1992-03-30 | WOUND HEALING |
AU14368/92A AU661840B2 (en) | 1991-03-28 | 1992-03-30 | Wound healing |
JP50694492A JP3333507B2 (en) | 1991-03-28 | 1992-03-30 | Wound healing |
GR990401862T GR3030924T3 (en) | 1991-03-28 | 1999-08-05 | Selective system scan for multizone radiotelephone subscriber units. |
US11/153,897 US20050287139A1 (en) | 1991-03-28 | 2005-06-16 | Wound healing |
US12/457,346 US20100152095A1 (en) | 1991-03-28 | 2009-06-08 | Wound healing |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9106678.7 | 1991-03-28 | ||
GB919106678A GB9106678D0 (en) | 1991-03-28 | 1991-03-28 | Wound healing |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US83844997A Division | 1991-03-28 | 1997-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992017206A1 true WO1992017206A1 (en) | 1992-10-15 |
Family
ID=10692386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/000570 WO1992017206A1 (en) | 1991-03-28 | 1992-03-30 | Wound healing |
Country Status (13)
Country | Link |
---|---|
US (4) | US5662904A (en) |
EP (1) | EP0585242B2 (en) |
JP (3) | JP3333507B2 (en) |
AT (1) | ATE182792T1 (en) |
AU (1) | AU661840B2 (en) |
CA (2) | CA2387247C (en) |
DE (1) | DE69229729T3 (en) |
DK (1) | DK0585242T4 (en) |
ES (1) | ES2136618T5 (en) |
GB (1) | GB9106678D0 (en) |
GR (1) | GR3030924T3 (en) |
IE (1) | IE921013A1 (en) |
WO (1) | WO1992017206A1 (en) |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993014782A1 (en) * | 1992-01-29 | 1993-08-05 | La Jolla Cancer Research Foundation | Methods of controlling the proliferation of macrophages |
WO1993019769A1 (en) * | 1992-03-28 | 1993-10-14 | The Victoria University Of Manchester | Wound healing and treatment of fibrotic disorders |
WO1994002595A1 (en) * | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
WO1994029452A2 (en) * | 1993-06-09 | 1994-12-22 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
WO1995013827A1 (en) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | A method for preventing or controlling cataract |
WO1995016032A1 (en) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE |
EP0669833A1 (en) * | 1992-10-29 | 1995-09-06 | Celtrix Pharmaceuticals, Inc. | USES OF TGF-$g(b) RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT |
WO1995024202A1 (en) * | 1994-03-07 | 1995-09-14 | Immusol, Inc. | Ribozyme therapy for restenosis |
WO1995024896A2 (en) * | 1994-03-15 | 1995-09-21 | Unilever Plc | Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne |
WO1995026203A1 (en) * | 1994-03-29 | 1995-10-05 | The Victoria University Of Manchester | Wound healing |
GB2288118A (en) * | 1994-03-29 | 1995-10-11 | Univ Manchester | Wound healing composition |
US5520926A (en) * | 1992-03-17 | 1996-05-28 | British Technology Group Limited | Method of using mannose phosphates for the treatment of fibrotic disorders |
WO1996025178A1 (en) * | 1995-02-15 | 1996-08-22 | The University Of Utah | ANTI-TRANSFORMING GROWTH FACTOR-β GENE THERAPY |
EP0737071A1 (en) * | 1993-06-15 | 1996-10-16 | Il- Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
WO1997005892A1 (en) * | 1995-08-04 | 1997-02-20 | The Victoria University Of Manchester | Use of betaglycan to reduce scarring |
WO1997013844A1 (en) * | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
WO1998035695A1 (en) * | 1997-02-13 | 1998-08-20 | The Victoria University Of Manchester | Wound healing |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
EP1009421A1 (en) * | 1997-08-27 | 2000-06-21 | President And Fellows Of Harvard College | Methods and compositions for enhanced wound healing |
WO2001027264A1 (en) * | 1999-10-15 | 2001-04-19 | Nihon University, School Juridical Person | Ribozymes to growth factor originating in human platelet |
US6277812B1 (en) | 1988-06-28 | 2001-08-21 | The Burnham Institute | Methods for inhibiting TGF-β activity |
EP0667784B1 (en) * | 1991-11-14 | 2003-03-05 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors and methods for preventing or reducing scarring |
WO2005051483A2 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
USRE39192E1 (en) | 1990-11-27 | 2006-07-18 | American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
USRE39298E1 (en) | 1990-11-27 | 2006-09-19 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
USRE39321E1 (en) | 1990-11-27 | 2006-10-03 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US7151169B2 (en) | 1999-04-30 | 2006-12-19 | Cambridge Antibody Technology Limited | Specific binding members for TGFβ1 |
US7229959B1 (en) * | 1990-11-27 | 2007-06-12 | The American National Red Cross | Supplemented fibrin matrix delivery systems |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
EP1992642A1 (en) | 2003-04-22 | 2008-11-19 | The University of Manchester | Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing |
US7700562B2 (en) | 2002-07-24 | 2010-04-20 | Renovo Limited | Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring |
US7713933B2 (en) * | 1995-10-21 | 2010-05-11 | Renovo Limited | Pharmaceutical composition containing an activin or inhibin stimulator |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571714A (en) * | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
US5177197A (en) * | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
GB2304047A (en) * | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
US6410519B1 (en) * | 1999-03-04 | 2002-06-25 | United States Surgical Corporation | Scar reduction |
US6630142B2 (en) | 1999-05-03 | 2003-10-07 | Zymogenetics, Inc. | Method of treating fibroproliferative disorders |
US7261881B1 (en) | 1999-05-20 | 2007-08-28 | Yale University | Modulation of angiogenesis and wound healing |
US6893637B1 (en) | 1999-10-21 | 2005-05-17 | Zymogenetics, Inc. | Method of treating fibrosis |
US20040197333A1 (en) * | 2000-02-10 | 2004-10-07 | Cornell Research Foundation, Inc. | Use of TGF-beta antagonists to inhibit tumor cell formation or progression |
AU9407501A (en) * | 2000-06-23 | 2002-04-22 | Medigenes | Agent for reduction of scar formation by using wound alkalinization |
US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
ATE474572T1 (en) * | 2000-11-30 | 2010-08-15 | Novodermix Internat Ltd | HEALING OF WOUNDS |
US20040235791A1 (en) * | 2002-01-25 | 2004-11-25 | Gruskin Elliott A. | Scar reduction |
PT1660057E (en) | 2003-08-27 | 2012-08-02 | Ophthotech Corp | Combination therapy for the treatment of ocular neovascular disorders |
KR101245983B1 (en) | 2004-03-31 | 2013-06-28 | 제넨테크, 인크. | Humanized anti-TGF-beta antibodies |
DE102004025881A1 (en) * | 2004-05-19 | 2006-01-05 | Beiersdorf Ag | Oligoribonucleotides for influencing hair growth |
US20070275874A1 (en) * | 2004-09-03 | 2007-11-29 | Yale University | Use of Leptin in Wound Healing |
US8109981B2 (en) | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
EP1945256B1 (en) * | 2005-10-25 | 2012-07-04 | Women's & Children's Health Research Institute | Methods and compositions for improving wound repair |
US8353881B2 (en) | 2005-12-28 | 2013-01-15 | Abbott Diabetes Care Inc. | Infusion sets for the delivery of a therapeutic substance to a patient |
US7981034B2 (en) | 2006-02-28 | 2011-07-19 | Abbott Diabetes Care Inc. | Smart messages and alerts for an infusion delivery and management system |
US9119582B2 (en) | 2006-06-30 | 2015-09-01 | Abbott Diabetes Care, Inc. | Integrated analyte sensor and infusion device and methods therefor |
US8932216B2 (en) | 2006-08-07 | 2015-01-13 | Abbott Diabetes Care Inc. | Method and system for providing data management in integrated analyte monitoring and infusion system |
US8206296B2 (en) | 2006-08-07 | 2012-06-26 | Abbott Diabetes Care Inc. | Method and system for providing integrated analyte monitoring and infusion system therapy management |
US8641618B2 (en) | 2007-06-27 | 2014-02-04 | Abbott Diabetes Care Inc. | Method and structure for securing a monitoring device element |
US8085151B2 (en) | 2007-06-28 | 2011-12-27 | Abbott Diabetes Care Inc. | Signal converting cradle for medical condition monitoring and management system |
KR20110074611A (en) * | 2008-10-21 | 2011-06-30 | 노보더믹스 인터내셔널 리미티드 | Composition for treatment of epithelial tissue |
WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
WO2010099364A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8642834B2 (en) | 2009-02-27 | 2014-02-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
CN108348578B (en) | 2015-08-04 | 2022-08-09 | 阿塞勒隆制药公司 | Methods for treating myeloproliferative disorders |
DK3628049T3 (en) | 2017-05-04 | 2023-08-14 | Acceleron Pharma Inc | TGF-BETA RECEPTOR TYPE-II FUSION PROTEINS AND USES THEREOF |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0258817A2 (en) * | 1986-08-30 | 1988-03-09 | BEHRINGWERKE Aktiengesellschaft | Use of monoclonal antibody in tumor therapy |
EP0282317A2 (en) * | 1987-03-13 | 1988-09-14 | Amgen Inc. | Purified platelet-derived growth factor and methods for purification thereof |
WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145676A (en) * | 1981-09-08 | 1992-09-08 | The Rockefeller University | Method and agents for promoting wound healing |
EP0105014B1 (en) * | 1982-09-24 | 1992-05-20 | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce | Repair of tissue in animals |
US5104977A (en) * | 1982-09-24 | 1992-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Purified transforming growth factor beta |
AU3108984A (en) * | 1983-06-03 | 1985-01-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Purified transforming growth factor-beta derived from human platelets and placentas |
US4708948A (en) * | 1984-04-20 | 1987-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Substantially purified tumor growth inhibitory factor |
DE3588058T3 (en) * | 1984-07-16 | 2005-04-07 | Celtrix Pharmaceuticals, Inc., Palo Alto | Cartilage-inducing polypeptide factors from bone |
US5168051A (en) * | 1985-03-22 | 1992-12-01 | Genentech, Inc. | Nucleic acid encoding TGF-β its uses |
IL78197A (en) * | 1985-03-22 | 1991-07-18 | Genentech Inc | Nucleic acid encoding tgf-beta and its uses |
US4886747A (en) * | 1985-03-22 | 1989-12-12 | Genentech, Inc. | Nucleic acid encoding TGF-β and its uses |
US5262319A (en) * | 1985-04-19 | 1993-11-16 | Oncogene Science, Inc. | Method for obtaining bone marrow free of tumor cells using transforming growth factor β3 |
IE60059B1 (en) * | 1985-04-19 | 1994-05-18 | Oncogene Science Inc | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof |
WO1989012101A1 (en) * | 1988-06-08 | 1989-12-14 | Genentech, Inc. | NUCLEIC ACID ENCODING TGF-beta3 AND ITS USE |
US4837381A (en) * | 1986-08-11 | 1989-06-06 | American Cyanamid Company | Compositions for parenteral administration and their use |
US4931548A (en) * | 1987-01-30 | 1990-06-05 | Techne Corporation | Heterodimer form of transforming growth factor-beta |
US5055447A (en) * | 1988-07-28 | 1991-10-08 | Genentech, Inc. | Method and compositions for the treatment and prevention of septic shock |
GB8823649D0 (en) * | 1988-10-07 | 1988-11-16 | Geistlich Soehne Ag | Chemical compounds |
US5135915A (en) * | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
IE61346B1 (en) * | 1988-11-02 | 1994-11-02 | Genentech Inc | A permeable material to fit around the teeth or gums of a mammal |
CA2005120A1 (en) * | 1988-12-15 | 1990-06-15 | Anthony F. Purchio | Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta |
US5118791A (en) * | 1989-05-25 | 1992-06-02 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
US5061786A (en) * | 1989-05-25 | 1991-10-29 | Genentech, Inc. | Biologically active polypeptides based on transforming growth factor-β |
EP0775742A3 (en) * | 1989-09-29 | 1998-01-14 | La Jolla Cancer Research Foundation | Inhibiting transforming growth factor beta to prevent accumulation of axtracellular matrix |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5147854A (en) * | 1990-05-22 | 1992-09-15 | Hoffmann-La Roche Inc. | Tgf-b compositions and method |
EP0538398A4 (en) * | 1990-06-25 | 1993-12-29 | Oncogene Science, Inc. | Tissue-derived tumor growth inhibitors, methods for preparation and uses thereof |
US5149801A (en) * | 1990-11-21 | 1992-09-22 | The Regents Of The University Of California | Boronated porphyrin compounds |
GB9101645D0 (en) * | 1991-01-25 | 1991-03-06 | British Bio Technology | Compounds |
WO1992013551A1 (en) * | 1991-02-04 | 1992-08-20 | Oncogene Science, Inc. | Inhibition of multidrug transport by transforming growth factor beta and uses thereof |
GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
CA2071137A1 (en) * | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
AU2738392A (en) * | 1991-11-11 | 1993-05-13 | Ciba-Geigy Ag | Novel hybrid transforming growth factors |
GB9205800D0 (en) * | 1992-03-17 | 1992-04-29 | British Tech Group | Treatment of fibrotic disorders |
GB9206861D0 (en) * | 1992-03-28 | 1992-05-13 | Univ Manchester | Wound healing and treatment of fibrotic disorders |
WO1995000103A2 (en) * | 1993-06-15 | 1995-01-05 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
DE69535976D1 (en) * | 1994-03-29 | 2009-08-13 | Renovo Ltd | Healing of wounds or fibrotic diseases using at least one agent against a growth factor |
-
1991
- 1991-03-28 GB GB919106678A patent/GB9106678D0/en active Pending
-
1992
- 1992-03-30 ES ES92907214T patent/ES2136618T5/en not_active Expired - Lifetime
- 1992-03-30 AT AT92907214T patent/ATE182792T1/en not_active IP Right Cessation
- 1992-03-30 AU AU14368/92A patent/AU661840B2/en not_active Ceased
- 1992-03-30 DE DE69229729T patent/DE69229729T3/en not_active Expired - Lifetime
- 1992-03-30 US US08/122,508 patent/US5662904A/en not_active Expired - Lifetime
- 1992-03-30 WO PCT/GB1992/000570 patent/WO1992017206A1/en active IP Right Grant
- 1992-03-30 DK DK92907214T patent/DK0585242T4/en active
- 1992-03-30 JP JP50694492A patent/JP3333507B2/en not_active Expired - Fee Related
- 1992-03-30 CA CA002387247A patent/CA2387247C/en not_active Expired - Lifetime
- 1992-03-30 EP EP92907214A patent/EP0585242B2/en not_active Expired - Lifetime
- 1992-03-30 IE IE101392A patent/IE921013A1/en not_active IP Right Cessation
- 1992-03-30 CA CA002105652A patent/CA2105652C/en not_active Expired - Lifetime
-
1999
- 1999-08-05 GR GR990401862T patent/GR3030924T3/en unknown
-
2002
- 2002-02-06 JP JP2002029691A patent/JP2002275094A/en active Pending
- 2002-04-08 US US10/117,351 patent/US20020187149A1/en not_active Abandoned
-
2005
- 2005-06-16 US US11/153,897 patent/US20050287139A1/en not_active Abandoned
- 2005-09-14 JP JP2005267284A patent/JP2006001949A/en active Pending
-
2009
- 2009-06-08 US US12/457,346 patent/US20100152095A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0258817A2 (en) * | 1986-08-30 | 1988-03-09 | BEHRINGWERKE Aktiengesellschaft | Use of monoclonal antibody in tumor therapy |
EP0282317A2 (en) * | 1987-03-13 | 1988-09-14 | Amgen Inc. | Purified platelet-derived growth factor and methods for purification thereof |
WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
Non-Patent Citations (1)
Title |
---|
See also references of EP0585242A1 * |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277812B1 (en) | 1988-06-28 | 2001-08-21 | The Burnham Institute | Methods for inhibiting TGF-β activity |
USRE39192E1 (en) | 1990-11-27 | 2006-07-18 | American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US7229959B1 (en) * | 1990-11-27 | 2007-06-12 | The American National Red Cross | Supplemented fibrin matrix delivery systems |
USRE39321E1 (en) | 1990-11-27 | 2006-10-03 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
USRE39298E1 (en) | 1990-11-27 | 2006-09-19 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
EP0667784B1 (en) * | 1991-11-14 | 2003-03-05 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors and methods for preventing or reducing scarring |
WO1993014782A1 (en) * | 1992-01-29 | 1993-08-05 | La Jolla Cancer Research Foundation | Methods of controlling the proliferation of macrophages |
US5520926A (en) * | 1992-03-17 | 1996-05-28 | British Technology Group Limited | Method of using mannose phosphates for the treatment of fibrotic disorders |
WO1993019769A1 (en) * | 1992-03-28 | 1993-10-14 | The Victoria University Of Manchester | Wound healing and treatment of fibrotic disorders |
US6331298B1 (en) | 1992-03-28 | 2001-12-18 | Renovo Limited | Wound healing and treatment of fibrotic disorders |
AU673161B2 (en) * | 1992-03-28 | 1996-10-31 | Renovo Limited | Wound healing and treatment of fibrotic disorders |
WO1994002595A1 (en) * | 1992-07-17 | 1994-02-03 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
US5693607A (en) * | 1992-10-29 | 1997-12-02 | Segarini; Patricia R. | Uses of TGF-β receptor fragment as a therapeutic agent |
EP0669833A1 (en) * | 1992-10-29 | 1995-09-06 | Celtrix Pharmaceuticals, Inc. | USES OF TGF-$g(b) RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT |
EP0669833A4 (en) * | 1992-10-29 | 1996-07-31 | Celtrix Pharma | USES OF TGF--g(b) RECEPTOR FRAGMENT AS A THERAPEUTIC AGENT. |
WO1994029452A2 (en) * | 1993-06-09 | 1994-12-22 | Ribozyme Pharmaceuticals, Inc. | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
WO1994029452A3 (en) * | 1993-06-09 | 1995-02-02 | Ribozyme Pharm Inc | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease |
EP0737071A1 (en) * | 1993-06-15 | 1996-10-16 | Il- Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
US5683988A (en) * | 1993-06-15 | 1997-11-04 | Il-Yang Pharm. Co., Ltd. | Anti-sense oligodeoxynucleotide to fibrogenic cytokine TGF-β and use thereof |
WO1995013827A1 (en) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | A method for preventing or controlling cataract |
WO1995016032A1 (en) * | 1993-12-09 | 1995-06-15 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE |
EP0750503A1 (en) * | 1994-03-07 | 1997-01-02 | Immusol, Inc. | Ribozyme therapy for restenosis |
WO1995024202A1 (en) * | 1994-03-07 | 1995-09-14 | Immusol, Inc. | Ribozyme therapy for restenosis |
US5834440A (en) * | 1994-03-07 | 1998-11-10 | Immusol Incorporated | Ribozyme therapy for the inhibition of restenosis |
WO1995024896A3 (en) * | 1994-03-15 | 1995-11-09 | Unilever Plc | Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne |
WO1995024896A2 (en) * | 1994-03-15 | 1995-09-21 | Unilever Plc | Use of antagonists of egf or tgf-alpha for the treatment and prophylaxis of acne |
AU710153B2 (en) * | 1994-03-29 | 1999-09-16 | Renovo Limited | Wound healing |
US5972335A (en) * | 1994-03-29 | 1999-10-26 | The Victoria University Of Manchester | Wound healing |
EP0968723A1 (en) * | 1994-03-29 | 2000-01-05 | The Victoria University Of Manchester | Healing of wounds or fibrotic disorders using at least one agent against a growth factor |
WO1995026203A1 (en) * | 1994-03-29 | 1995-10-05 | The Victoria University Of Manchester | Wound healing |
GB2288118A (en) * | 1994-03-29 | 1995-10-11 | Univ Manchester | Wound healing composition |
US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
WO1996025178A1 (en) * | 1995-02-15 | 1996-08-22 | The University Of Utah | ANTI-TRANSFORMING GROWTH FACTOR-β GENE THERAPY |
WO1997005892A1 (en) * | 1995-08-04 | 1997-02-20 | The Victoria University Of Manchester | Use of betaglycan to reduce scarring |
US6060460A (en) * | 1995-08-04 | 2000-05-09 | The Victoria University Of Manchester | Use of betaglycan to reduce scarring |
WO1997013844A1 (en) * | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
US7368111B2 (en) | 1995-10-06 | 2008-05-06 | Cambridge Antibody Technology Limited | Human antibodies specific for TGFβ2 |
EP0945464A1 (en) * | 1995-10-06 | 1999-09-29 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
US7713933B2 (en) * | 1995-10-21 | 2010-05-11 | Renovo Limited | Pharmaceutical composition containing an activin or inhibin stimulator |
WO1998035695A1 (en) * | 1997-02-13 | 1998-08-20 | The Victoria University Of Manchester | Wound healing |
US6319907B1 (en) | 1997-02-13 | 2001-11-20 | Renovo Limited | Wound healing |
EP1009421A1 (en) * | 1997-08-27 | 2000-06-21 | President And Fellows Of Harvard College | Methods and compositions for enhanced wound healing |
EP1009421A4 (en) * | 1997-08-27 | 2001-04-18 | Harvard College | Methods and compositions for enhanced wound healing |
US7151169B2 (en) | 1999-04-30 | 2006-12-19 | Cambridge Antibody Technology Limited | Specific binding members for TGFβ1 |
US7078390B1 (en) | 1999-10-15 | 2006-07-18 | Gentier Biosystems Incorporation | Ribozymes to growth factor originating in human platelet |
WO2001027264A1 (en) * | 1999-10-15 | 2001-04-19 | Nihon University, School Juridical Person | Ribozymes to growth factor originating in human platelet |
US7700562B2 (en) | 2002-07-24 | 2010-04-20 | Renovo Limited | Use of —furin—“convertase” inhibitors in the treatment of fibrosis and scarring |
EP1992642A1 (en) | 2003-04-22 | 2008-11-19 | The University of Manchester | Collagen fibrils carrying bioactive heterologous domains and their use in e.g. wound healing |
WO2005051483A3 (en) * | 2003-11-20 | 2005-07-07 | Angiotech Int Ag | Electrical devices and anti-scarring agents |
WO2005051483A2 (en) * | 2003-11-20 | 2005-06-09 | Angiotech International Ag | Electrical devices and anti-scarring agents |
Also Published As
Publication number | Publication date |
---|---|
US20020187149A1 (en) | 2002-12-12 |
GR3030924T3 (en) | 1999-11-30 |
GB9106678D0 (en) | 1991-05-15 |
US5662904A (en) | 1997-09-02 |
IE921013A1 (en) | 1992-10-07 |
CA2387247A1 (en) | 1992-10-15 |
DK0585242T3 (en) | 1999-12-06 |
EP0585242B2 (en) | 2007-03-07 |
JPH06506205A (en) | 1994-07-14 |
JP2002275094A (en) | 2002-09-25 |
EP0585242B1 (en) | 1999-08-04 |
ES2136618T5 (en) | 2007-10-16 |
JP2006001949A (en) | 2006-01-05 |
US20050287139A1 (en) | 2005-12-29 |
CA2387247C (en) | 2009-05-19 |
EP0585242A1 (en) | 1994-03-09 |
ES2136618T3 (en) | 1999-12-01 |
DE69229729T2 (en) | 2000-01-13 |
DK0585242T4 (en) | 2007-07-02 |
CA2105652C (en) | 2005-09-06 |
DE69229729T3 (en) | 2007-10-18 |
US20100152095A1 (en) | 2010-06-17 |
JP3333507B2 (en) | 2002-10-15 |
AU661840B2 (en) | 1995-08-10 |
ATE182792T1 (en) | 1999-08-15 |
DE69229729D1 (en) | 1999-09-09 |
AU1436892A (en) | 1992-11-02 |
CA2105652A1 (en) | 1992-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0585242B1 (en) | Wound healing | |
US5788967A (en) | Composition and method for enhancing wound healing | |
US6331298B1 (en) | Wound healing and treatment of fibrotic disorders | |
WO1994000484A1 (en) | Scar inhibitory factor and use thereof | |
JPH10502530A (en) | Factors that grow tissue in vitro | |
JPH07504650A (en) | Inhibition of transforming growth factor β to prevent extracellular matrix accumulation | |
CA2031817C (en) | Use of thrombospondin to promote wound healing | |
AU617795B2 (en) | Heparin-binding proteins, dna coding for them, processes for producing them as well as therapeutic preparations containing them | |
WO1998004245A1 (en) | Use of transglutaminase modulators to promote wound healing | |
Khouri et al. | De novo generation of permanent neovascularized soft tissue appendages by platelet-derived growth factor. | |
Ksander | Exogenous growth factors in dermal wound healing | |
US8357655B2 (en) | Wound healing peptides and methods of use thereof | |
JPH07316066A (en) | Wound healing agent | |
Ksander et al. | Exogenous transforming growth factor‐β2 enhances connective tissue formation in transforming growth factor‐β1—deficient, healing‐impaired dermal wounds in mice | |
US20240016893A1 (en) | Compositions and methods for treating wounds | |
WO2002078728A2 (en) | Peptides for the treatment of wound contracture | |
Klein | Modulation of cutaneous wound healing mechanisms to affect characteristics of healing | |
WO1992013888A1 (en) | Epithelial cell wound healing compositions and method | |
WO1999042132A1 (en) | Use of anti-cd44 monoclonal antibody to enhance wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MG MW NO PL RO RU SD US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992907214 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2105652 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08122508 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1992907214 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992907214 Country of ref document: EP |